<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580903</url>
  </required_header>
  <id_info>
    <org_study_id>MPNPH</org_study_id>
    <nct_id>NCT02580903</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms</brief_title>
  <acronym>MPNPH</acronym>
  <official_title>Pulmonary Hypertension in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms; an Observational Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective study aiming to clarify the prevalence of pulmonary
      hypertension in patients with Myeloproliferative Neoplasms and their prognosis.

      All patients attending our department with the above mentioned neoplasms will be offered
      inclusion in this study. All will have an echo performed and patients identified as being at
      risk of pulmonary hypertension will be offered complete investigation as specified by the
      European Cardiology Association.

      All patients will be followed up for a total of five years to identify prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of pulmonary hypertension at initial presentation and first echo</measure>
    <time_frame>Initial recruitment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary hypertension while under follow-up</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiology</intervention_name>
    <description>Only a small subsample will require CT and right heart catherisation</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All patients will submit a blood sample for later analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending our outpatient clinic with Myeloproliferative Neoplasms
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myeloproliferative Neoplasms (PV, ET, PMF according to WHO classification)

        Exclusion Criteria:

          -  Pregnancy

          -  Lack of informed consent

          -  Age &lt; 18 years

          -  Cognitive dysfunctions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Brabrand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette Brabrand, MD</last_name>
    <phone>+4566113333</phone>
    <email>mette.brabrand@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanne Vestergaard, MD PhD</last_name>
    <phone>+4566113333</phone>
    <email>hanne.vestergaard@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Brabrand, MD</last_name>
      <phone>+4566113333</phone>
      <email>mette.brabrand@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mette Brabrand</investigator_full_name>
    <investigator_title>Staff Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

